BL1332 clears phase 1b: Yehia Hashad, MD, on what's next

Ocular surface pain remains a persistent clinical challenge, with few therapies designed to interrupt the neurosensory pathways that drive it rather than address the underlying inflammation indirectly. Ophthalmology Times spoke with Yehia Hashad, MD, executive vice president of research and development and chief medical officer at Bausch + Lomb, about the company's investigational TRPV1 antagonist BL1332 and what a recent phase 1b capsaicin challenge study revealed about its mechanism.